Charles River Laboratories International Valuation
Is CRL * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CRL * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CRL * (MX$4048.97) is trading below our estimate of fair value (MX$4166.73)
Significantly Below Fair Value: CRL * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRL *?
Other financial metrics that can be useful for relative valuation.
What is CRL *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$11.19b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.4x |
Enterprise Value/EBITDA | 14.8x |
PEG Ratio | 1.9x |
Price to Earnings Ratio vs Peers
How does CRL *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 53.2x | ||
BRKR Bruker | 28x | 3.6% | US$11.2b |
TECH Bio-Techne | 62.7x | 15.0% | US$12.7b |
ERF Eurofins Scientific | 42.8x | 20.2% | €11.0b |
DIVISLAB Divi's Laboratories | 79.1x | 24.0% | ₹1.1t |
CRL * Charles River Laboratories International | 25.2x | 13.6% | Mex$11.2b |
Price-To-Earnings vs Peers: CRL * is good value based on its Price-To-Earnings Ratio (25.2x) compared to the peer average (53.2x).
Price to Earnings Ratio vs Industry
How does CRL *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: CRL * is good value based on its Price-To-Earnings Ratio (25.2x) compared to the Global Life Sciences industry average (31.9x).
Price to Earnings Ratio vs Fair Ratio
What is CRL *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 25.2x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CRL *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.